Status:
COMPLETED
Febuxostat Effect on Chronic Kidney Disease Progression And Carotid Intima-Media Thickness
Lead Sponsor:
Ain Shams University
Conditions:
Carotid Intima- Media Thickness
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study aimed to evaluate the impact of febuxostat on both carotid intima-media thickness and disease progression in individuals with chronic kidney disease
Detailed Description
For all participants, comprehensive data collection was performed, encompassing detailed medical histories including patients' clinical and demographic characteristics (age, gender, BMI, associated co...
Eligibility Criteria
Inclusion
- Age of 18 years or older
- CKD stages III to IV
- Asymptomatic hyper uricemia
- Stable dose of all medications including ACEIs or ARBs for blood pressure control at least three months before enrolling
Exclusion
- Comprised active infections.
- Acute kidney injury.
- Active and advanced malignancy.
- History of hypersensitivity to febuxostat.
- Women who are taking oral contraceptives, pregnant or lactating
- Patients with established cardiovascular disease.
- Patients with liver disease.
- Patients receiving mercaptopurine, theophylline and azathioprine.
- Patients on steroids or other immunosuppressive treatment.
Key Trial Info
Start Date :
May 24 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 24 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06997952
Start Date
May 24 2024
End Date
August 24 2024
Last Update
May 31 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain Shams University
Cairo, Egypt, Egypt, 11111